Genome-editing tools are programmable artificial nucleases, mainly including zinc-finger nucleases, transcription activator-like effector nucleases and clustered regularly interspaced short palindromic repeat (CRISPR). By recognizing and cleaving specific DNA sequences, genome-editing tools make it possible to generate site-specific DNA double-strand breaks (DSBs) in the genome.
| INTRODUCTION
The Human Genome Project, which was completed in 2003, uncovered the code of human beings. Subsequently, different genome sequencing projects have been launched around the world, including the international 1,000 Genomes Project, the Cancer Genome Project of the USA, the Precision Medicine Project of the USA, and the Precision Medicine Project of China. These genome sequencing projects mainly focus on cancer and rare diseases. It is estimated that approximately 100 million to 2 billion human genomes would be sequenced by 2025. 1 The explosive increase of genomic data will reveal unprecedented genetic diversity and potential drug targets. However, the relationship between the genotype and phenotype is still elusive and needs to be modeled and studied in vitro and in vivo.
Therefore, developing efficient and cost-effective methodology with which to manipulate the genome is extremely important for both basic research and for developing new therapeutic strategies.
| From gene targeting to genome editing
For many years, gene targeting was the only strategy that could precisely manipulate the genome of model organisms. 2 However, gene targeting depended on germline-competent embryonic stem cells (ESCs), which for a long time were restricted to mice and, later, rats. [3] [4] [5] [6] [7] In addition, gene targeting takes advantage of spontaneous homologous recombination (HR) at the target site that is mainly induced by replication fork stalling in the cell, and therefore, the efficiency is relatively low. After positive-negative selection, several hundred targeted ESC clones must be screened by either Southern blotting or the polymerase chain reaction (PCR) to identify the correctly targeted clones.
Traditional gene targeting is time-consuming and labor-intensive. 2 What is worse, in human ESCs, the recombination efficiency is much lower than that of mouse ESCs. 8 The low efficiency hampers therapeutic applications based on manipulating the genome of human ESCs. On the other hand, the advent of somatic cell nuclear transfer (SCNT)
technology produced the first cloned animal, Dolly, in 1996. 9, 10 Subsequently, SCNT has been widely applied on livestock. [11] [12] [13] [14] [15] Combined with transgenic and gene-targeting technology, SCNT has been used to generate transgenic or gene-targeted sheep, pig, bovine, etc.. [16] [17] [18] [19] [20] [21] [22] [23] [24] However, the efficiency of SCNT is also very low. [16] [17] [18] [19] [20] [21] [22] [23] [24] In 1994 and 1995, two independent studies showed that DSBs induced by I-SceI meganuclease could stimulate the HR machinery by more than 100-fold in mouse cells. 25, 26 These early studies raised the concept of genome-editing. However, the meganuclease recognition site, such as 5′-TAGGGATAACAGGGTAAT-3′ for I-SceI, must be introduced into the genome before meganuclease application. In addition, it is difficult to reprogram recognition specificity, thus limiting the utility of meganucleases. 27, 28 Subsequently, many scientists have devoted efforts to developing programmable artificial nucleases to induce site-specific DNA DSBs. 28, 29 Genome-editing utilizes molecular scissors, such as programmable artificial nucleases, to cleave the target site in the genome. The DSB is repaired by either nonhomologous end joining (NHEJ) or high-fidelity HR. 30 NHEJ is an error-prone DNA repair pathway that usually leads to base deletions and insertions at the target site. Base deletions and insertions could result in frame-shift mutations in the target gene, thus disrupting target gene expression. Additionally, when two sites are simultaneously cleaved, it is feasible to induce large fragment deletions, inversions and chromosome translocations. 31 In the presence of donor plasmid or single-strand DNA oligos, DNA DSBs can also be repaired by HR. 31 HR is a high-fidelity DNA repair mechanism that
can induce a precise point mutation and exogenous gene integration at the target site.
There are mainly three kinds of molecular scissors that are used in genome-editing, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeat (CRISPR). Both ZFNs and TALENs are fusion proteins of DNA-binding domains and nonspecific FokI nuclease domains, and they work as a dimer. To cleave the target DNA, the recognition sites of the monomers must be arranged in an inverted orientation and separated by several base pairs. 32 For ZFNs, the spacer region is approximately 4-7 BP; however, the spacer region of TALENs is 12-21 BP. 31 After binding to the target site, the FokI nuclease domain will dimerize and cleave the target site.
The DNA-binding domain of ZFN is adapted from the C 2 H 2 zincfinger domain of the mouse Zif268 protein or the artificial domain QQR. 28, 33 The mouse Zif268 C 2 H 2 zinc-finger domain folds into a ββα structure with a zinc ion in the center, and it recognizes three nucleotides via amino acids in the α helix. X-ray crystal structure analysis revealed that amino acids at position −1,+2, +3 and +6 are involved in DNA recognition. 34 Therefore, in theory, it is possible to generate a zinc-finger domain that can recognize all 64 triplet nucleotides by randomizing the amino acids at these positions. The zinc finger DNA-recognition code was uncovered as well. [35] [36] [37] However, later research revealed that zinc fingers have a preference for 5′-GNN-3′
triplets, thus limiting the target DNA range of ZFNs. 32 Three to four zinc fingers were assembled modularly to generate customized ZFNs that can recognize 9-12 BP DNA. However, each zinc finger in the monomer does not act completely independently because the sequence specificity of a given zinc-finger domain is affected by the neighboring zinc-finger domains. 38 In addition, this phenomenon is called a context-dependent effect, which results in unexpectedly high failure rates for the recognition of target DNA by the modular assembly. 39 To circumvent this problem, selection-based design strategies based on phage display, bacterial two-hybrid systems or bacterial one-hybrid systems have been developed. [40] [41] [42] [43] [44] However, these are time-consuming and labor-intensive. Despite the emergence of several simpler approaches, such as context-dependent assembly (CoDA) and optimized two-finger modules, [45] [46] [47] it is still challenging to generate ZFNs with high activity. 48 Therefore, even though ZFNs were developed in 1996, it was mainly used by only specialist laboratories and rich laboratories.
Similar to ZFNs, the TALEN is a hybrid of a TALE repeat domain and FokI nuclease domain. 49 The TALE repeat is derived from the TAL effector, such as avrBs3, of the plant pathogenic bacteria named
Xanthomonas. 50 The TAL effector is an important virulence factor that activates host cell gene expression by binding DNA via a tandem repeat of 6.5 to 33.5 highly conservative TALE repeats. 50 Each TALE repeat is composed of 33-35 amino acids, of which amino acids at positions 4, 12, 13 and 32 are hypervariable. 50 In 2009, two independent groups revealed that the DNA binding specificity of the TALE repeat is encoded in the hypervariable positions 12 and 13. 51, 52 The NN, NI, HD and NG amino acids will bind G, A, C and T, respectively. 51, 52 Unlike zinc-finger domains, each TALE repeat only recognizes one nucleotide. 31, 49, [51] [52] [53] Additionally, no apparent context-dependent effect was observed between neighboring TALE repeats, 51, 52 which made it much easier to generated an active TALEN by modular assembly. 31 Usually, 15-18 TALE repeats are joined together to recognize 15-18 nucleotides. TALEN has been widely used by different laboratories around the world. It has been applied in plant, Xenopus, yeast, Drosophila, zebrafish, mouse, rat, pig and human cells subsequent to its debut in 2010. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] However, the procedure used to ligate TALE repeats is relatively complex and difficult and therefore requires expertise to be achieved. Furthermore, the highly repetitive sequences in TALENs made it improbable to deliver TALENs by lentiviral vectors. These drawbacks limit the application of TALENs.
Unlike ZFNs and TALENs, CRISPR is an RNA-protein complex composed of gRNA and Cas (CRISPR-associated) effector (similar to Cas9, Cpf1, C2C1, etc.). It specifies the target DNA, which contains a protospacer adjacent motif (PAM), by hybridizing with the guide sequence located at either the 5′ end or the 3′ end of the gRNA. [65] [66] [67] [68] [69] [70] After hybridization, the endonuclease activity of the Cas effector is activated, resulting in DNA DSBs. [71] [72] [73] [74] [75] [76] To make a site-specific CRISPR, only the guide sequence of the gRNA needs to be manipulated, thus avoiding complex protein engineering technologies. In addition, gene-specific gRNAs can be designed and cloned in 3-4 days. As a result of its ease and high efficiency, CRISPR has been applied in a variety of species subsequent to the first report of its reprogrammable activity in 2012. 68 Today, CRISPR has become a revolutionary technology similar to PCR in the 1980s. It will be a revolution for both fundamental research and disease therapy.
| DEVELOPMENT OF CRISPR
CRISPR was first discovered in Escherichia coli as five highly similar 29-bp direct-repeat sequences that were separated by 32-bp dissimilar spacer sequences in 1987 by Yoshizumi Ishino. 77 It was later shown to be involved in the acquired immune system of bacteria and archaea, protecting hosts from viruses and exogenous plasmids using crRNA (CRISPR RNA) and Cas effector protein. [78] [79] [80] [81] The history of the initial discovery of CRISPR has been reviewed elsewhere. [82] [83] [84] Here, we focus on the history of developing CRISPR as a genome-editing tool and the major applications of CRISPR ( Figure 1 ). 85 Both systems need trans-activating CRISPR (tracrRNA) to aid the assembly of the active nuclease. These two milestone studies revealed the following important features of CRISPR 68, 85 :
i The specificity of CRISPR is encoded in the first 20 nucleotides at the 5′ end of the crRNA, which is mainly determined by the approximately 12-nucleotide seed sequence that is upstream from the FIGURE 1 Developmental history of CRISPR PAM. The PAM sequence of SpCas9 is 5′-NGG-3′, whereas that of StCas9 is 5′-NGGNG-3′.
ii Cas9 could tolerate up to 6 contiguous mismatches outside the seed sequence.
iii crRNA and tracrRNA could be replaced with a chimeric gRNA, combining the features of both RNAs.
iv Targeted DNA cleavage by Cas9 depends on the PAM sequence.
v Cas9 cleaves target DNA at a site that is 3 nucleotides upstream of the PAM sequence, leaving a blunt end.
vi Two independent nuclease domains are responsible for the cleavage of each strand of target DNA. The RuvC domain and the HNH domain cleave the nontarget stand and the target strand, respectively.
vii Both RuvC-inactivated and HNH-inactivated mutants are still functional, and they could nick target DNA.
In addition, these two studies also proposed that the CRISPR system could be developed as a novel genome-editing tool, similar to ZFNs and TALENs. 68, 85 However, whether the prokaryotic CRISPR system would work in the eukaryotic cell remained unknown. 86 In January 2013, Feng Zhang's group, George Church's group, Jenniffer Doudna's group and Jin-Soo Kim's group independently developed the CRISPR system, using SpCas9 to facilitate targeted genome-editing in eukaryotic cells. [65] [66] [67] 87 All four study groups showed that CRISPR could efficiently cleave endogenous genomic sites in human cells and that chimeric gRNA could replace the tracrRNA:crRNA duplex. [65] [66] [67] 87 However, the length of the chimeric gRNA was not the same, and the gRNA backbone from George Church's group, which was the longest, is widely used today. [65] [66] [67] 87 Furthermore, Feng Zhang and George Church confirmed that homology-directed repair could be achieved in cellulo using either wild-type Cas9 or Cas9 nickase. 65, 67 Feng Zhang also found that CRISPR could simultaneously cleave two genomic sites, confirming the robustness of CRISPR. 67 In addition, Feng Zhang's study also revealed that the type II CRISPR system from Streptococcus thermophiles LMD-9 could cleave target sites in human cells. 67 In the following months, scientists reported efficient genome-editing in different species, ranging from bacteria to cattle. [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] Compared with ZFNs and TALENs, CRISPR is much easier and cheaper to be customized because genomic sites with a PAM sequence could be a target site, Cas9 is universal and only gRNAs need to be cloned for each target. The high efficiency and simplicity enable the wide application of CRISPR. However, there are still some knowledge gaps.
| Specificity of CRISPR
The first gap is the off-target effect, which is paramount for disease model construction and human gene therapy. It has been shown that Cas9 could tolerate RNA-DNA mismatch in vitro and in vivo. 67, 68 However, to date, a systemic study of the off-target effects has not been conducted. In August 2013, four independent studies revealed that CRISPR has obvious off-target effects in human cells. [103] [104] [105] [106] The specificity of CRISPR is gRNA-dependent, which is affected by the number and distribution of the mismatches between gRNA and DNA. [103] [104] [105] [106] Surprisingly, hundreds of single nucleotide variations (SNVs) and indels were found in the F1 generation mice corrected by one gRNA targeting Pde6b. 107 However, some SNVs could be resulted from the differences between individuals. Besides, the genomic DNA was found that the DNA recognition specificity of the pDBD domain was improved in the chimera with little effect on the on-target cleavage activity. 113 Furthermore, based on the X-ray structure results, investigators also aimed to enhance the specificity of Cas9 by generating SpCas9 mutants with reduced helicase activity or binding energy with target DNA. 114, 115 In two studies, Feng Zhang and Keith Joung generated eSpCas9 and Cas9-HF with different point mutations. 112, 113 Whether SpCas9 with all these mutations will still be active or more specific is an interesting question.
All of the above studies focused on Cas9 protein. However, the specificity could also be improved by optimizing gRNA. David Liu reported that gRNA with a truncated backbone at the 3′ end exhibited improved specificity; however, this was at the expense of lower ontarget activity. 105 Jin-Soo Kim proposed that adding two extra GG to the 5′ end of gRNA could reduce off-target effects. 116 One month later, Eugene Koonin reported that C2C1, which is adapted from the type VB CRISPR system, could also cleave target DNA in human cell lysate but not in cellulo. 70 In June 2016, Feng
Zhang discovered that C2C2 is a single RNA-guided RNase in vitro.
However, RNA targeting by C2C2 leads to cell growth restriction in bacteria. 130 The development of functional specific RNA-guided RNase will generate good replacements for siRNA, and labeling endogenous RNA in cells with inactive RNase will shed light on RNA trafficking.
| Precise genome-editing by CRISPR
Cleaving the target DNA is not the ultimate goal, whereas scarless genome surgery is. The HR rate is usually below 1/10 −5 . DNA DSBs induced by CRISPR will stimulate HR. However, NHEJ always outcompetes HR. To achieve the goal of scarless DNA surgery, scientists have developed many approaches to improve HR efficiency.
In September 2013, George Church found that generating 5′ overhangs with Cas9 nickase induced high HR efficiency. 106 In December 2014, Jennifer Doudna reported that HR efficiency could be increased by nucleofection of Cas9 ribonucleoprotein and repair template into synchronized S-phase cells. 131 In March 2015, two independent groups showed that inhibiting the NHEJ pathway using the small chemical molecule SCR7 could promote HR. 132, 133 Later, two independent studies showed that RS-1 could enhance HR efficiency in human cells and rabbit embryos. 134, 135 In addition, coexpression of adenovirus 4 E1b55k or the E4orf6 gene could also promote HR in mammalian cells. 133 Because single-strand DNA is more recombinogenic than double-strand DNA, scientists have also tried to stimulate HR using single-strand DNA (ssDNA). 136 In August 2015, Masato Ohtsuka's group was the first to report the efficient knock-in of a 514 nucleotides long artificial miRNA in mice using long ssDNA with a 55 nucleotides homology arm. 137 Later, Yomoji Mashimo's group reported highly efficient integration of the long single-strand GFP coding sequence by HR. 138 They also found that single-strand DNA oligo with microhomology to both donor DNA and targeted sites could enhance the efficiency of donor DNA integration. 138 Jacob Corn found that Cas9 first releases the 3′ end of the nontarget strand after cleavage, and that designing ssDNA complementing the nontarget stand could enhance HR efficiency. target integration (HITI). 143 They found that the use of the same gRNA to simultaneously cleave the target gene and donor vector in dividing 293 T cells could precisely and efficiently integrate the donor vector into the target site, and the efficiency was at least two-fold higher than that of MMEJ (60% versus 20%). In addition, at the junction of integration, most of the sequenced junction did not contain indels. 143 In additional studies using nondividing neu- 144, 145 Following DNA replication, this conversion will lead to a C to T (or G to A) substitution. Base-editing is over 100-fold more efficient than generating point mutations by HDR. [144] [145] [146] The fusion protein composed of dCas9 (or Cas9 nickase) and AID could convert C (or G) to the other three bases (A, T or G) in target DNA when repaired by error-prone base-excision repair. 145, 146 Chang and colleagues took advantage of the diverse point mutations generated by Cas9-AID to screen ABL point mutations, which render K562 cells resistant to Imatinib, aiming to uncover the mechanism underlying drug resistance at a single-base resolution level. 146 Recently, Jin-soo Kim and our group independently applied base-editing in mouse embryos to generate mutant mice. 147, 228 Although gRNA-guided deamination has been shown to be specific by others, we observed obvious proximalsite deamination at cytidines 3 BP downstream the PAM sequence of the target in mouse embryos, which is in line with the data recently reported by George Church. 148 This proximalsite deamination might be site-dependent, and it might be caused by the unwinding of double-strand DNA, rendering single-strand DNA susceptible to deamination by cytidine deaminase. Therefore, more effort should be devoted to improving the specificity of deamination. Based on the very high efficiency of base-editing in precise point mutation generation, it might represent an easier and more efficient way of generating disease models and correcting disease mutants in patients.
Knowledge gaps about precise genome-editing are being filled day-by-day; therefore, scarless gene repair may not be an impossible dream.
| HUMAN DISEASE MODEL PRODUCTION AND DRUG SCREENING USING CRISPR
Human disease cell and animal models are very important for deciphering the mechanism of disease development and developing new therapeutics. Additionally, genome-wide drug target screening is very critical for discovering the appropriate target gene. As a result of the high efficiency and versatility of CRISPR, it has been widely used in these areas. DNA template containing the disease mutation but not the silent mutations. Therefore, the silent mutations are removed, leaving behind only the disease mutation. 150 The CORRECT strategy facilitates the scarless introduction of only the disease mutation. 150 
| Human disease cell model

| Human disease animal model
As a result of its ease of use and high efficiency, CRISPR has been applied to generate human disease models in a variety of model animals, including zebrafish, mice, rats, pigs and monkeys. By contrast to conventional gene targeting strategies, the founder animal generated by CRISPR is mosaic, which has been shown to be useful for mimicking human disease, such as Leber congenital amaurosis. 151 Masugi Nishihara produced a muscular dystrophy rat model and found that the F0 rat already exhibited degenerative changes in its muscles. 152 Considering the advantage of rats in the evaluation of pharmacological effects and toxicity, 153 this model may be useful in drug tests for muscular dystrophy therapy. In humans, a Park2 or Pink1 mutation would trigger autosomal recessive early-onset Parkinson's disease.
Liangxue Lai efficiently constructed this disease pig model using CRISPR/Cas9 and the somatic cell nuclear transfer method. Moreover, no mosaic mutations or off-target effects were detected. 154 Qi Zhou generated the first living p53 homozygous mutant monkey via zygote injection. 155 In addition, Xingxu Huang utilized CRISPR to generate a Dax1 knockout monkey. The phenotype of the founder monkey resembles that of AHC-HH (adrenal hypoplasia congenita-hypogonadotropic hypogonadism) patients, whereas the Dax1-null mouse failed to recapitulate the disease phenotype. CRISPR showed high efficiency in the generation of biallelic gene mutant monkeys, highlighting the power of CRISPR in generating disease monkey models. It is expected that the monkey model of biallelic mutant p53 can mimic the human genetic disorder in tumorigenesis to a great extent. 156 CRISPR has been widely applied for the one-step generation of a loss-of-function disease gene animal model using different animal models via zygote gene-editing. Nevertheless, traditional whole-body gene mutation or disruption animal models cannot completely reflect the genetic complexity of cancer. Cancer is caused by the stepwise accumulation of somatic mutations. As a result of its high efficiency and ability to be delivered using viral vectors, CRISPR has the potential to directly induce gene disruptions in adult tissues. Previously, mouse models for the study of cancer genes were traditionally generated by transgenesis or gene targeting using ESCs. 157 Jacks Tyler was the first to use CRISPR in adult tissue to generate a cancer model. 158 A plasmid was delivered expressing Cas9 and sgRNAs that targeted the tumor suppressor genes Pten and p53 to the liver by hydrodynamic injection.
Although the Pten and p53 disruption efficiency (4.0 ± 0.1% for Pten and 6.4 ± 0.1% for p53) was low, it was sufficient to induce hepatic tumors. 158 In addition, Jacks Tyler has also used this approach to establish a lung adenocarcinoma mouse model. 159 Furthermore, CRISPR has been used to generate oncogenic chromosome rearrangements in adult lungs. 160, 161 Chiarle Roberto and Ventura Andrea independently utilized CRISPR, which was delivered by a viral vector, to cleave the Eml4 and Alk loci. 160, 161 DNA double-strand breaks caused by CRISPR at these two loci resulted in the Eml4-Alk fusion, a frequently observed fusion in a subset of human nonsmall cell lung cancer. 160, 161 The
Eml4-Alk fusion did cause lung tumors in adult mice, and the tumor was sensitive to ALK inhibitors, which was consistent with the clinical therapeutic results. 160, 161 In addition to lung and liver cancer, Feng
Zhang's group used adenoassociated viral (AAV) vectors to deliver CRISPR into the adult mouse brain to target Mecp2, an X-linked gene associated with Rett syndrome. 162 SpCas9 was driven by a neuronspecific promoter to achieve cell-specific Mecp2 disruption. CRISPR has become a powerful genome-editing tool in adult tissues. In another group, they established mouse models of myeloid malignancy by engineering combinatorial genes. 163 Up to five genes were modified in a single mouse hematopoietic stem cell (HSC) by delivering sgRNAs and Cas9 using lentiviral vectors. The disruption of cancer suppressor genes leads to clonal outgrowth and transformation into acute leukemia. 163 Delivery of CRISPR into adult tissues by viral vectors, including lentivirus, AAV and even adenovirus, has revolutionized disease model construction. It is expected that it will also revolutionize human gene therapy.
| Genome-wide genetic screening by CRISPR
In addition to using CRISPR to generate disease models, CRISPR has been utilized to identify drug targets by genome-wide screening.
Although genome-wide RNAi screening has been used for many years, the off-target effects and incomplete gene expression repression are still major concerns for functional screen assays. In December 2013, Feng Zhang and Eric Lander simultaneously reported genome-scale gene knockout screening by CRISPR. 164, 165 Genome-wide screen by CRISPR provides a powerful methodology for developing new disease therapeutics. On one hand, it can be used to discover new drug target genes. Recently, Christopher Vakoc has utilized CRISPR screening to screen drug targets in murine acute myeloid leukemia. In addition to six known drug targets, he discovered 19 new targets that may be useful for cancer therapy. 166 On the other hand, it can be used to screen drug-resistant genes for personal medicine clinics. However, there are many false-positive results in genome-wide screens by CRISPR.
Replacing the constitutively expressed Cas9 with a doxycycline-inducible Cas9 may be a good choice.
Taken together, CRISPR paves new avenues for the generation of appropriate human disease models, clarifying the underlying mechanism of disease occurrence and progression. Furthermore, it will also promote the development of new therapeutics. Intriguingly, studies have shown that delivering CRISPR alone or together with donor DNA could alleviate disease phenotypes in adult Duchenne muscular dystrophy mice and tyrosinemia mice. 142, [169] [170] [171] [172] These studies highlight the therapeutic potential of CRISPR for genetic diseases. Recently, CRISPR has been used to correct human blood disease mutations, such as β-thalassemia, hemophilia, chronic granulomatous disease and Fanconi anemia, in patient iPS cells and fibroblasts. [173] [174] [175] [176] Moreover, as a step toward the clinical application of CRISPR, Matthew Porteus corrected sickle cell disease-causing β-globin mutations in patient HSCs by CRISPR and AAV. 177 He plans to produce edited cells for a clinical trial in 2018. Independently, sickle cell disease mutations were corrected in HSCs by CRISPR and ssDNA oligo. 178 Additionally, CRISPR has been applied to correct genetic mutations in solid tissues. The Duchenne muscular dystrophy-causing mutation in the dystrophin gene has been edited to restore gene function in human iPS cells and myoblasts. 179, 180 In addition, the functional restoration of cystic fibrosis mutations in human intestinal stem cells has been reported. 181 These pioneering studies confirmed the feasibility of correcting mutations in primary human cells. In the future, these gene-edited primary cells might be transferred into patients to treat or even cure disease.
In addition to repairing defect genes in situ, CRISPR could be used to promote functional therapeutic gene integration into safe harbor loci, such as AAVS1, albumin and CCR5. 182 Compared with traditional gene therapy, inserting therapeutic genes at safe harbor loci allows for transgene silencing, which is very important for the long-term relief of disease symptoms. Moreover, gene knock-in at the safe harbor loci also prevents multiple copy integration and neighboring gene expression interference, which are important with respect to minimizing the risk of gene therapy. 
| Treating viral infections with CRISPR
In addition, CRISPR could also be applied to treat viral infections.
CCR5 and CXCR4 are coreceptors for HIV-1 infection; people with homozygous Ccr5 △32 mutations are healthy and resistant to HIV-1 infection. 188, 189 Timothy Brown is the only patient to be cured of AIDS. 190 Brown was transplanted with homozygous ccr5 △32 mutant HSCs after being diagnosed with acute myeloid leukemia.
A previous study using ZFN confirmed that knocking out Ccr5
and Cxcr4 in CD4 + T cells could make them resistant to HIV-1 infection. 191, 192 In vivo studies have shown that NSG mice transplanted with ZFN-edited Ccr5-null HSCs or Cxcr4-null CD4 + T cells exhibit higher CD4 + T cell and lower HIV-1 levels after HIV-1 infection. 189, 193 Although Ccr5 and Cxcr4 were not disrupted in all cells, HIV-1 infection enriched the Ccr5-and Cxcr4-null cells,
showing that even low editing efficiency might achieve a therapeutic benefit. 189, 193 These proof-of-concept studies provide evidence for using gene-modified HSCs in clinical HIV-1 therapy.
Soon after the first report of genome-editing by CRISPR, CRISPR was used to ablate Ccr5 and Cxcr4 in human induced pluripotent stem cells, HSCs and CD4 + T cells. [194] [195] [196] [197] [198] These studies confirm the protective potential of gene-editing by CRISPR. [195] [196] [197] [198] Consistent with ZFN-mediated Ccr5 disruption, Ccr5-null cells generated by CRISPR also have a selective advantage over wild-type cells. 198 Although CRISPR targeting of Ccr5 and Cxcr4 was shown to be specific, the off-target cleavage detection methods used in these studies (surveyor nuclease assay and TA cloning sequencing) were not very sensitive. 137, 138 In addition, a previous study using the T7E1 assay has shown that the targeting of Ccr5 using CRISPR has obvious off-target effects. 199 Therefore, it is prudent to improve and validate the specificity of CRISPR before any clinical application. 
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Furthermore, CRISPR could also reduce HBsAg levels, HBeAg levels and viral DNA load in chronically infected cells. 212 These studies suggest that CRISPR may serve as a novel therapeutic modality for HBV infection. Treating latent viral infection with CRISPR is promising; however, some challenges remain to be solved, such as the delivery method and the specificity of CRISPR, as well as the rapid evolution of viruses. 213, 214 4.4 | Germline gene modification by CRISPR
To correct genetic mutations in somatic cells, CRISPR has been utilized to correct cataracts, muscle dystrophy and hearing loss in mouse zygotes. [215] [216] [217] By combining CRISPR and ssDNA oligos, six silent mutations were introduced into β-globin, and the Ccr5 △32 mutation was generated in human tripronuclear embryos. 218, 219 Recently, CRISPR was applied to correct disease mutations (G6pd) in normal human zygotes. 220 According to these studies, mosaicism and potential off-target cleavage are still very important concerns for human zygote genome-editing by CRISPR. Moreover, human germline genomeediting is very controversial as a result of ethical, societal and legal concerns, and it needs to be thoroughly discussed and investigated before any clinical trials. The latest report from the US National Academies of Science, Engineering and Medicine (NASEM) permitted human germline genome-editing under strict regulation and oversight to eliminate severe genetic diseases that have no other treatment options.
The NASEM also emphasized that germline genome-editing therapy
should not be performed before the safety and efficacy of the technique are tested. In addition, human enhancements are not permitted. 221 
| Delivery
Choosing an appropriate way to deliver CRISPR into cells is critical for its therapeutic application. CRISPR could be introduced as DNA, mRNA and protein. DNA could be delivered using viral vectors, lipid nanoparticles, injection and electroporation, which have been reviewed recently. 222 Moreover, after delivering CRISPR by AAV into adult or neonatal Dunchenne muscular dystrophy mouse models, muscular dystrophy was obviously rescued, as shown by a significant improvement of muscle force. [167] [168] [169] [170] These proof-of-concept studies proved the feasibility of curing genetic diseases using an AAV-delivered CRISPR system. [167] [168] [169] [170] Delivering CRISPR as DNA, however, is inefficient for gene-editing in primary cells. Therefore, the gRNA:
Cas9 complex (ribonucleoprotein) has been delivered into primary cells either via lipid nanoparticles or electroporation to improve geneediting efficiency. 223 In addition, gRNA has been chemically modified to improve the stability of RNA. 224 More work is still urgently needed to explore the most suitable delivery methods for CRISPR-mediated gene therapy. could also lead to unimaginable disaster. Therefore, rigorous regulation is needed to monitor the application of CRISPR. In addition, germline gene-editing should not proceed until there is broad societal consensus and until the risks are thoroughly investigated. 226, 227 
| SAFETY CONCERNS
